Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2026-05-27 Major Shareholding Noti…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Change in substantial holding KHPL 2 pages 711.1KB
Major Shareholding Notification Classification · 87% confidence The document is an ASX Form 604 “Notice of change of interests of substantial holder,” detailing share acquisitions that change voting power above thresholds. This clearly falls under a Major Shareholding Notification, not a report or announcement of results.
2026-05-27 English
Cleansing Notice 1 page 223.6KB
Share Issue/Capital Change Classification · 91% confidence The document is an official announcement by Vectus Biosystems of the issuance of 7,910,000 new fully paid ordinary shares under a placement and includes the required cleansing notice under Section 708A of the Corporations Act. This is clearly a share issuance/capital change announcement rather than a full financial report, management update, or dividend notice. It falls under the "Share Issue/Capital Change" category.
2026-05-26 English
Application for quotation of securities - VBS 6 pages 18.3KB
Share Issue/Capital Change Classification · 93% confidence The document is the ASX Appendix 2A “Application for quotation of securities” filed by Vectus Biosystems Limited, detailing the quotation of 7,910,000 newly issued fully paid ordinary shares, the issue price, total capital raised, and updated issued capital. This is a formal announcement of new share issuance and capital change, matching the Share Issue/Capital Change category (SHA).
2026-05-26 English
Placement of Shares 2 pages 286.7KB
Share Issue/Capital Change Classification · 93% confidence The document is a company announcement detailing a placement of 7,910,000 new fully paid ordinary shares at $0.10 per share, including attendant options, to raise $791,000. It covers the terms of the share issue, ASX listing rule compliance, use of proceeds, and quotations. This clearly constitutes an announcement of a new share issue and capital change rather than an earnings release or annual report.
2026-05-21 English
Proposed issue of securities - VBS 6 pages 22.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 3B form providing detailed information about a proposed issue of securities (placement of ordinary shares and attaching options) by Vectus Biosystems Limited. It outlines terms, conditions, issue dates, pricing, and listing rule compliance for new share issuance. This is a capital raising announcement regarding a new share issue, fitting the “Share Issue/Capital Change” category.
2026-05-21 English
Updated Corporate Presentation 21 pages 1.0MB
Investor Presentation Classification · 85% confidence The document is a slide deck with detailed information on company strategy, clinical data, market opportunity, capital structure, and leadership formatted as a presentation (e.g., forward‐looking statements, summary form, slide structure). It is intended for investors (including summary financials, pipeline overview, next catalysts). It is not a formal regulatory filing of financial statements or an earnings release but an Investor Presentation.
2026-05-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.